1. Home
  2. CXE vs RANI Comparison

CXE vs RANI Comparison

Compare CXE & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.88

Market Cap

117.9M

Sector

Finance

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$1.28

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXE
RANI
Founded
1989
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.9M
130.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CXE
RANI
Price
$3.88
$1.28
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.67
AVG Volume (30 Days)
62.9K
1.0M
Earning Date
01-01-0001
03-30-2026
Dividend Yield
4.36%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
N/A
$1,200,000.00
Revenue This Year
N/A
$414.59
Revenue Next Year
N/A
$30.15
P/E Ratio
$51.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$0.39
52 Week High
$3.67
$3.87

Technical Indicators

Market Signals
Indicator
CXE
RANI
Relative Strength Index (RSI) 72.96 47.79
Support Level $3.75 $1.21
Resistance Level $3.84 $1.42
Average True Range (ATR) 0.03 0.10
MACD 0.01 0.01
Stochastic Oscillator 90.00 62.32

Price Performance

Historical Comparison
CXE
RANI

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: